OVERVIEW

Tesamorelin, CJC-1295 (no DAC), and Ipamorelin 12mg (blend) is a combination of growth hormone–releasing peptides designed to stimulate the body’s natural production of growth hormone. Tesamorelin and CJC-1295 (no DAC) are analogs of growth hormone–releasing hormone (GHRH), which signal the pituitary gland to release growth hormone in a pulsatile, physiologic manner. The “no DAC” version of CJC-1295 allows for shorter-acting, controlled release rather than prolonged stimulation. Ipamorelin is a selective growth hormone–releasing peptide (GHRP) that acts on ghrelin receptors to further enhance growth hormone secretion while minimizing effects on cortisol and prolactin. Together, these peptides are believed to work synergistically to optimize endogenous growth hormone output.

The 12mg blend is typically supplied as a lyophilized powder for research or experimental use and requires reconstitution prior to administration. In research settings, such combinations are explored for potential effects on body composition, muscle recovery, fat metabolism, and sleep quality. Possible side effects may include mild water retention, increased appetite, tingling sensations, or temporary changes in glucose levels. This peptide blend is not approved for general medical use outside specific regulatory indications. Because it influences hormonal pathways, use should be guided by a qualified healthcare professional to ensure appropriate dosing, monitoring, and safety during research or specialized applications.